SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:uu-488560"
 

Sökning: id:"swepub:oai:DiVA.org:uu-488560" > Modulation of hypot...

  • Ferreira, VitorCSIC UAM, Inst Invest Biomed Alberto Sols IIBM, Madrid, Spain.;ISCIII, Ctr Invest Biomed Red Diabet & Enfermedades Metab, Madrid, Spain. (författare)

Modulation of hypothalamic AMPK phosphorylation by olanzapine controls energy balance and body weight

  • Artikel/kapitelEngelska2022

Förlag, utgivningsår, omfång ...

  • Elsevier,2022
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-488560
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-488560URI
  • https://doi.org/10.1016/j.metabol.2022.155335DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Background: Second-generation antipsychotics (SGAs) are a mainstay therapy for schizophrenia. SGA-treated patients present higher risk for weight gain, dyslipidemia and hyperglycemia. Herein, we evaluated the effects of olanzapine (OLA), widely prescribed SGA, in mice focusing on changes in body weight and energy balance. We further explored OLA effects in protein tyrosine phosphatase-1B deficient (PTP1B-KO) mice, a preclinical model of leptin hypersensitivity protected against obesity. Methods: Wild-type (WT) and PTP1B-KO mice were fed an OLA-supplemented diet (5 mg/kg/day, 7 months) or treated with OLA via intraperitoneal (i.p.) injection or by oral gavage (10 mg/kg/day, 8 weeks). Readouts of the crosstalk between hypothalamus and brown or subcutaneous white adipose tissue (BAT and iWAT, respectively) were assessed. The effects of intrahypothalamic administration of OLA with adenoviruses expressing constitutive active AMPK alpha 1 in mice were also analyzed. Results: Both WT and PTP1B-KO mice receiving OLA-supplemented diet presented hyperphagia, but weight gain was enhanced only in WT mice. Unexpectedly, all mice receiving OLA via i.p. lost weight without changes in food intake, but with increased energy expenditure (EE). In these mice, reduced hypothalamic AMPK phosphorylation concurred with elevations in UCP-1 and temperature in BAT. These effects were also found by intrahypothalamic OLA injection and were abolished by constitutive activation of AMPK in the hypothalamus. Additionally, OLA i. p. treatment was associated with enhanced Tyrosine Hydroxylase (TH)-positive innervation and less sympathetic neuron-associated macrophages in iWAT. Both central and i.p. OLA injections increased UCP-1 and TH in iWAT, an effect also prevented by hypothalamic AMPK activation. By contrast, in mice fed an OLA-supplemented diet, BAT thermogenesis was only enhanced in those lacking PTP1B. Our results shed light for the first time that a threshold of OLA levels reaching the hypothalamus is required to activate the hypothalamus BAT/iWAT axis and, therefore, avoid weight gain. Conclusion: Our results have unraveled an unexpected metabolic rewiring controlled by hypothalamic AMPK that avoids weight gain in male mice treated i.p. with OLA by activating BAT thermogenesis and iWAT browning and a potential benefit of PTP1B inhibition against OLA-induced weight gain upon oral treatment.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Folgueira, CintiaCtr Nacl Invest Cardiovasc CNIC, Madrid 28029, Spain. (författare)
  • Guillen, MariaCSIC UAM, Inst Invest Biomed Alberto Sols IIBM, Madrid, Spain. (författare)
  • Zubiaur, PabloUniv Autonoma Madrid, Inst Invest Sanitaria La Princesa IP, Hosp Univ La Princesa, Clin Pharmacol Dept,Sch Med, Madrid, Spain.;UICEC Hosp Univ La Princesa, Inst Invest Sanitaria La Princesa IP, Platform SCReN Spanish Clin Res Network, Madrid, Spain. (författare)
  • Navares, MarcosUICEC Hosp Univ La Princesa, Inst Invest Sanitaria La Princesa IP, Platform SCReN Spanish Clin Res Network, Madrid, Spain. (författare)
  • Sarsenbayeva, AsselUppsala universitet,Klinisk diabetologi och metabolism(Swepub:uu)asssa458 (författare)
  • Lopez-Larrubia, PilarCSIC UAM, Inst Invest Biomed Alberto Sols IIBM, Madrid, Spain. (författare)
  • Eriksson, JanUppsala universitet,Klinisk diabetologi och metabolism(Swepub:uu)janer909 (författare)
  • Pereira, Maria J.,1981-Uppsala universitet,Klinisk diabetologi och metabolism(Swepub:uu)marpe927 (författare)
  • Abad-Santos, FranciscoUniv Autonoma Madrid, Inst Invest Sanitaria La Princesa IP, Hosp Univ La Princesa, Clin Pharmacol Dept,Sch Med, Madrid, Spain.;UICEC Hosp Univ La Princesa, Inst Invest Sanitaria La Princesa IP, Platform SCReN Spanish Clin Res Network, Madrid, Spain.;Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain. (författare)
  • Sabio, GuadalupeCtr Nacl Invest Cardiovasc CNIC, Madrid 28029, Spain. (författare)
  • Rada, PatriciaCSIC UAM, Inst Invest Biomed Alberto Sols IIBM, Madrid, Spain.;ISCIII, Ctr Invest Biomed Red Diabet & Enfermedades Metab, Madrid, Spain. (författare)
  • Valverde, Angela M.CSIC UAM, Inst Invest Biomed Alberto Sols IIBM, Madrid, Spain.;ISCIII, Ctr Invest Biomed Red Diabet & Enfermedades Metab, Madrid, Spain. (författare)
  • CSIC UAM, Inst Invest Biomed Alberto Sols IIBM, Madrid, Spain.;ISCIII, Ctr Invest Biomed Red Diabet & Enfermedades Metab, Madrid, Spain.Ctr Nacl Invest Cardiovasc CNIC, Madrid 28029, Spain. (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Metabolism: Elsevier1370026-04951532-8600

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy